Novo Nordisk to Launch Ozempic in India Amidst Growing Diabetes and Obesity Market

Ozempic Launch in India

• 🇩🇰 Danish drugmaker Novo Nordisk is set to launch its popular diabetes drug Ozempic in India this month, according to sources.
• 🎯 The move aims to strengthen Novo Nordisk's foothold in a region with the second-highest number of people with type 2 diabetes globally.

Market Opportunity in India

• 📈 India's rising obesity rates make it a key battleground for drug manufacturers targeting the fast-growing weight loss treatment market.
• 💰 Analysts project this market to reach $150 billion annually by the end of the decade.

Ozempic and Its Use

• 💉 Ozempic, a once-weekly injectable, is approved by the US FDA for type 2 diabetes.
• 🍽️ It is also widely used off-label for weight loss due to its appetite-suppressing effects.
• 🌾 Novo Nordisk's other semaglutide-based drug, Wegovy, is approved for weight loss.

Regulatory Approval and Competition

• ✅ Novo Nordisk received Indian regulatory approval in September to import and sell Ozempic.
• ⏱️ The company hopes to launch the drug as early as possible, though specific timelines and pricing details are not yet public.
• ⚔️ Novo Nordisk faces stiff competition from US rival Eli Lilly, whose drug Mounjaro is approved for both diabetes and weight loss and became India's top-selling drug by value in October.